$VIRX
Viracta Therapeutics, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020022937 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $120.0K $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.230M $2.440M
YoY Change -8.61% -27.38%
% of Gross Profit
Research & Development $3.690M $3.248M
YoY Change 13.61% -18.17%
% of Gross Profit
Depreciation & Amortization $2.000K $2.000K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $4.457M $3.248M
YoY Change 37.22% -18.17%
Operating Profit -$4.457M
YoY Change
Interest Expense $0.00 -$260.0K
YoY Change -100.0% -192.53%
% of Operating Profit
Other Income/Expense, Net $0.00 $90.00K
YoY Change -100.0% -9.09%
Pretax Income -$5.780M -$5.860M
YoY Change -1.37% -19.39%
Income Tax
% Of Pretax Income
Net Earnings -$4.417M -$5.860M
YoY Change -24.62% -19.43%
Net Earnings / Revenue -3680.83%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.818M -$3.467M
COMMON SHARES
Basic Shares Outstanding 67.58M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.40M $24.80M
YoY Change -5.65% -2.36%
Cash & Equivalents $14.56M $24.81M
Short-Term Investments $3.400M
Other Short-Term Assets $7.300M $1.600M
YoY Change 356.25% 6.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $30.70M $26.40M
YoY Change 16.29% -1.86%
LONG-TERM ASSETS
Property, Plant & Equipment $1.000K $1.200M
YoY Change -99.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $800.0K $1.400M
YoY Change -42.86% 1300.0%
TOTAL ASSETS
Total Short-Term Assets $30.70M $26.40M
Total Long-Term Assets $800.0K $1.400M
Total Assets $31.50M $27.80M
YoY Change 13.31% 2.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $900.0K $900.0K
YoY Change 0.0% -10.0%
Accrued Expenses $2.900M $3.100M
YoY Change -6.45% -6.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.500M $6.000M
YoY Change -8.33% -17.81%
Total Short-Term Liabilities $9.300M $10.00M
YoY Change -7.0% -13.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $700.0K
YoY Change -85.71%
Total Long-Term Liabilities $100.0K $700.0K
YoY Change -85.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.300M $10.00M
Total Long-Term Liabilities $100.0K $700.0K
Total Liabilities $9.401M $10.67M
YoY Change -11.88% -8.03%
SHAREHOLDERS EQUITY
Retained Earnings -$688.6M
YoY Change
Common Stock $11.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$32.71M $17.09M
YoY Change
Total Liabilities & Shareholders Equity $31.49M $27.80M
YoY Change 13.26% 2.96%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$4.417M -$5.860M
YoY Change -24.62% -19.43%
Depreciation, Depletion And Amortization $2.000K $2.000K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$3.658M -$6.113M
YoY Change -40.16% -6.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $12.96M $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $10.69M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 17.23M
YoY Change -100.0% 8689.8%
NET CHANGE
Cash From Operating Activities -3.658M -6.113M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 17.23M
Net Change In Cash 7.213M 11.12M
YoY Change -35.11% -298.06%
FREE CASH FLOW
Cash From Operating Activities -$3.658M -$6.113M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9416000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16364000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2020Q1 us-gaap Liabilities
Liabilities
9401000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
11769000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
681000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
11000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
698562000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
27543000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9000
CY2019Q4 us-gaap Liabilities
Liabilities
9697000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
11769000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
698881000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-688575000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-682800000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
22086000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31487000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37240000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120000
CY2020Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2019Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
2000
CY2019Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3690000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3248000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
748000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13705000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5775000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5860000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
CY2020Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-37000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5744000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12957000
CY2019Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1406000
CY2019Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
7944000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10690000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17228000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7213000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11115000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18261000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13696000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25474000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24811000
CY2019Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3228000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1362000
CY2019Q1 snss Legal Expenses Accrued As Cost Of Equity Financing
LegalExpensesAccruedAsCostOfEquityFinancing
-98000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3993000
CY2019Q1 snss Issuance Of Common And Preferred Stock In Underwritten Offering Net Of Issuance Costs
IssuanceOfCommonAndPreferredStockInUnderwrittenOfferingNetOfIssuanceCosts
18536000
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
54000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
17086000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s condensed consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to <font style="color:#000000;">valuation of marketable securities, equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting</font>. </p>
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26657000
CY2020Q1 snss Cash And Cash Equivalents Restricted Cash And Marketable Securities
CashAndCashEquivalentsRestrictedCashAndMarketableSecurities
28900000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27882000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20554000
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22495000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22495000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
26656000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10293000
CY2019Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
16363000
CY2019Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
1000
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2019 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q1 us-gaap Notes Payable
NotesPayable
5500000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
436000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
294000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
730000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
681000
CY2020Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2019Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000

Files In Submission

Name View Source Status
0001564590-20-022937-index-headers.html Edgar Link pending
0001564590-20-022937-index.html Edgar Link pending
0001564590-20-022937.txt Edgar Link pending
0001564590-20-022937-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g1dv1muffbih000001.jpg Edgar Link pending
gsusaoncj2yf000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20200331.htm Edgar Link pending
snss-20200331.xml Edgar Link completed
snss-20200331.xsd Edgar Link pending
snss-20200331_cal.xml Edgar Link unprocessable
snss-20200331_def.xml Edgar Link unprocessable
snss-20200331_lab.xml Edgar Link unprocessable
snss-20200331_pre.xml Edgar Link unprocessable
snss-ex101_90.htm Edgar Link pending
snss-ex311_8.htm Edgar Link pending
snss-ex321_6.htm Edgar Link pending
snss-ex41_109.htm Edgar Link pending